Scintigraphic Imaging of Body Neuroendocrine Tumors

References

• 1 PearseAG. The APUD concept and hormone production. Clin Endocrinol Metab1980;9:211–222.
  MedlineGoogle Scholar
• 2 KvolsLK. Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors. Gastroenterology1993;105:1909–1911.
  MedlineGoogle Scholar
• 3 de HerderWW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptor in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer2003;10:451–458.
  MedlineGoogle Scholar
• 4 KaltsasG, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol2004;151:15–27.
  MedlineGoogle Scholar
• 5 van der HarstE, de Herder WW, Bruining HA, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab2001;86:685–693.
  MedlineGoogle Scholar
• 6 KrempfM, Lumbroso J, Mornex R, et al. Use of I-131 MIBG in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab1991;72: 455–461.
  MedlineGoogle Scholar
• 7 ErikssonB, Bergstrom M, Orlefors H, et al. Use of PET in neuroendocrine tumors: in vivo applications and in vitro studies. Q J Nucl Med2000;44: 68–76.
  MedlineGoogle Scholar
• 8 PasqualiC, Rubello D, Sperti C, et al. Neuroendocrine tumor imaging: can F-18 fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg1998;22:588–592.
  MedlineGoogle Scholar
• 9 KhafagiFA, Shaprio B, Fig LM, et al. Labetalol reduces I-131-MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med1989;30: 481–489.
  MedlineGoogle Scholar
• 10 Babovic-VuksanovicD, Constantinou CL, Rubin J, Rowland CM, Schaid DJ, Karnes PS. Familial occurrence of carcinoid tumors and association with other neoplasms. Cancer Epidemiol Bio-markers Prev1999;8:715–179.
  Google Scholar
• 11 ModlinIM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer1997;79:813–829.
  MedlineGoogle Scholar
• 12 ObergK. Carcinoid tumors, carcinoid syndrome, and related disorders. In: Larsen PR, Kronenberg HM, Melmed S, Plansky KS, eds. Williams textbook of endocrinology. 10th ed. Philadelphia, Pa: Saunders, 2003; 661–690.
  Google Scholar
• 13 TyceGM. Biochemistry of serotonin. In: van Houtte PM, ed. Serotonin and the cardiovascular system. New York, NY: Raven, 1985; 1–13.
  Google Scholar
• 14 UlrichCD 2nd, Holtmann M, Miller LJ. Serotonin and vasoactive intestinal peptide receptors: members of a unique family of G protein–coupled receptors. Gastroenterology1998;114:382–397.
  MedlineGoogle Scholar
• 15 MeijerWG, Sief CV, Hollema H, et al. Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem2003;49: 586–593.
  MedlineGoogle Scholar
• 16 HansonMW, Feldman JM, Blinder RA, Moore JO, Coleman RE. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology1989;172(3):699–703.
  Google Scholar
• 17 van der LelyAJ, de Herder WW. Carcinoid syndrome: diagnosis and medical management. Arq Bras Endocrinol Metabol2005;49(5):850–860.
  MedlineGoogle Scholar
• 18 ZollingerRM, Ellison EH. Primary peptide ulceration of the jejunum associated with islet cell tumor of the pancreas. Ann Surg1955;142:709–728.
  MedlineGoogle Scholar
• 19 RoyPK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine2000;79:379–411.
  MedlineGoogle Scholar
• 20 KrenningEP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. In: Freeman LM, ed. Nuclear medicine annual. New York, NY: Raven, 1995; 1–50.
  Google Scholar
• 21 MekoJB, Doherty GM, Siegel BA, Norton JA. Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors. Surgery1996;120(6):975–983.
  MedlineGoogle Scholar
• 22 WarnerRR. Enteroendocrine tumor other than carcinoid: a review of clinically significant advances. Gastroenterology2005;128:1668–1684.
  MedlineGoogle Scholar
• 23 van BeekAP, de Haas ER, van Vioten WA, et al. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol2004;151:531–537.
  MedlineGoogle Scholar
• 24 GregianinM, Macri C, Bui F, et al. Whole body and tomographic scan with In-111 pentetriotide: preliminary data. Q J Nucl Med1995;39(4 suppl 1):124–126.
  MedlineGoogle Scholar
• 25 VernerJV, Morrison AB. Endocrine pancreatic islet disease with diarrhea: report of a case due to diffuse hyperplasia of no beta islet tissue with a review of 54 additional cases. Arch Intern Med1974;133:492–501.
  MedlineGoogle Scholar
• 26 O’DorisioTM, Mehkjian HS, Gaginella TS. Medical therapy of vipomas. Endocrinol Metab Clin North Am1989;18:545–550.
  MedlineGoogle Scholar
• 27 SmithSL, Branton SA, Avino AJ, et al. Vasoactive intestinal polypeptide secreting islet tumors: a 5-year experience and review of the literature. Surgery1998;124:1050–1055.
  MedlineGoogle Scholar
• 28 PowerN, Reznek RH. Imaging pancreatic islet cell tumors. Imaging2002;14(2):147–159.
  Google Scholar
• 29 EckhauserFE, Cheung PS, Vinik AI, Strodel WE, Lloyd RV, Thompson NW. Nonfunctioning malignant tumors of the pancreas. Surgery1986; 100(6):978–988.
  MedlineGoogle Scholar
• 30 RambaldiPF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111)In pentetreotide in the PET era. Q J Nucl Med Mol Imaging2005;49(3):225–235.
  MedlineGoogle Scholar
• 31 WittelesRM, Kaplan EL, Roizen MF. Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice. Arch Intern Med2000;160:2521–2524.
  MedlineGoogle Scholar
• 32 HeronE, Chatellier G, Billaud E, et al. The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma. Ann Intern Med1996;125:300–303.
  MedlineGoogle Scholar
• 33 IliasI, Pacak K. Clinical problem solving: Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab2004;89(2):479–491.
  MedlineGoogle Scholar
• 34 BlakeMA, Kalra MK, Maher MM, et al. Pheochromocytoma: an imaging chameleon. RadioGraphics2004;24(suppl 1):S87–S99.
  Google Scholar
• 35 PacakK, Chrousos GP, Koch CA, et al. Pheochromocytoma: progress in diagnosis, therapy, and genetics. In: Margioris AN, Chrousos GP, eds. Adrenal disorders. Totowa, NJ: Humana, 2001; 479–523.
  Google Scholar
• 36 ShulkinBL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology1999;212:35–41.
  Google Scholar
• 37 WhartonSM, Davis A. Familial paraganglioma. J Laryngol Otol1996;110:688–690.
  MedlineGoogle Scholar
• 38 RaoAB, Koeller KK, Adair CF. Paragangliomas of the head and neck: radiologic-pathologic correlation. RadioGraphics1999;19:1605–1632.
  Google Scholar
• 39 MarxSJ, Stralakis CA. Multiple endocrine neoplasia. J Intern Med2005;257:2–5.
  MedlineGoogle Scholar
• 40 ThakkerRV. Multiple endocrine neoplasia type I. Endocrinol Metab Clin North Am2000;29:541–567.
  MedlineGoogle Scholar
• 41 ScarsbrookAF, Thakker RV, Wass JA. Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. RadioGraphics2006;26:433–451.
  Google Scholar
• 42 KulkeMH, Mayer RJ. Carcinoid tumors. N Engl J Med1999;340:858–868.
  MedlineGoogle Scholar
• 43 BrandiML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and 2. J Clin Endocrinol Metab2001;86:5658–5671.
  MedlineGoogle Scholar
• 44 ClarkeSE, Rankin SC. The thyroid gland. Imaging2002;14:103–114.
  Google Scholar
• 45 KhanN, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-fluro-2-deoxy-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control2005;12(4):254–260.
  MedlineGoogle Scholar
• 46 de GrootJW, Links TP, Jager PL, et al. Impact of FDG-PET in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol2004;11:786–794.
  MedlineGoogle Scholar